ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

COVID-19 antibody therapy 85% effective, Vir and GSK say

Drugmakers seek consent to use treatment that works on more contagious variants

Britain's GSK and America's Vir Biotechnology say their experimental COVID-19 antibody therapy can reduce hospitalization and deaths by 85%.   © Reuters

Vir Biotechnology and Britain's GSK plan to seek emergency use authorization for their experimental COVID-19 antibody therapy after interim data from a study showed 85% reduction in hospitalization and deaths among patients, the companies said.

The move brings the antibody therapy one step closer to becoming another weapon against the pandemic, with similar therapies from Eli Lilly and Regeneron Pharmaceuticals receiving recommendations from U.S. and European health regulators earlier this year.

Vir and GSK said in a joint statement on Wednesday that an independent panel recommended stopping further enrolment in the late-stage trial of the therapy due to evidence of "profound efficacy."

The companies said they plan to use the results of the study to seek emergency use authorization from the U.S. Food and Drug Administration and regulatory approvals in other countries.

Antibody treatments are designed to decrease the severity of COVID-19 among patients diagnosed with the infection.

Vir and GSK also said that a new laboratory study showed the therapy, VIR-7831, was equally effective against the UK, South African and Brazilian variants of the coronavirus.

Vir and GSK announced a partnership last year to research COVID-19 treatments.

(Reuters)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more